Suggested remit: To appraise the clinical and cost effectiveness of lenalidomide with rituximab within its marketing authorisation for untreated follicular lymphoma.
Please note that following on from information provided to NICE by the company in July 2018, the appraisal of Lenalidomide for untreated follicular lymphoma [ID1245] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1245
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in July 2018, the appraisal of Lenalidomide for untreated follicular lymphoma [ID1245] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 01 August 2018 | Suspended. Company update |
| 01 August 2018 | Note added to the project documents |
| 08 June 2018 - 06 July 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 27 June 2018 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual